Investigational New Drugs

Công bố khoa học tiêu biểu

* Dữ liệu chỉ mang tính chất tham khảo

Sắp xếp:  
A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma
Investigational New Drugs - Tập 24 - Trang 89-94 - 2006
Karl D. Lewis, John A. Thompson, Jeffrey S. Weber, William A Robinson, Steven O'Day, Jose Lutzky, Sewa S. Legha, Simon Floret, Francis Ruvuna, Rene Gonzalez
Metastatic melanoma continues to be a very difficult disease to treat. Options are limited and often have very little impact on the course of the disease. The objective of the current study was to evaluate the efficacy and safety of continuously administered Apomine (SR-45023A), a novel bisphosphonate, in patients with previously treated metastatic malignant melanoma. Adult patients with previousl...... hiện toàn bộ
A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
Investigational New Drugs - Tập 34 - Trang 740-749 - 2016
J. E. Grilley-Olson, P. L. Bedard, A. Fasolo, M. Cornfeld, L. Cartee, A. R. Abdul Razak, L.-A. Stayner, Y. Wu, R. Greenwood, R. Singh, C. B. Lee, J. Bendell, H. A. Burris, G. Del Conte, C. Sessa, J. R. Infante
Introduction This Phase Ib trial investigated the safety, tolerability, and recommended phase 2 dose for the pan-PI3K/mTOR inhibitor, GSK2126458 (GSK458), and trametinib combination when administered to patients with advanced solid tumors. Patients and Methods Patients with advanced solid tumors received escalating doses of GSK458 (once or twice daily, and continuous or in...... hiện toàn bộ
Effects of the potential chemopreventive agent DMU-135 on adenoma development in the ApcMin+ mouse
Investigational New Drugs - Tập 24 - Trang 459-464 - 2006
S. Sale, R. G. Tunstall, K. C. Ruparelia, P. C. Butler, G. A. Potter, W. P. Steward, A. J. Gescher
DMU-135 (3,4-Methylenedioxy-3′,4′,5′-trimethoxy chalcone) is a novel anticancer prodrug designed to be activated into a potent tyrosine kinase inhibitor by the tumour selective enzyme activity of the cytochrome P450 enzyme CYP1B1. CYP1B1 is selectively expressed in a wide variety of tumours including colon. The hypothesis was tested that DMU-135 would inhibit ApcMin/+ mouse gastrointestinal adenom...... hiện toàn bộ
Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma
Investigational New Drugs - Tập 25 - Trang 265-270 - 2006
Matthew D. Galsky, Svetlana Mironov, Alexia Iasonos, Joseph Scattergood, Mary G. Boyle, Dean F. Bajorin
Purpose: The purpose of this single-center phase II study was to determine the activity of pemetrexed administered as second-line therapy in patients with advanced urothelial carcinoma. Methods: Patients with advanced urothelial carcinoma that had relapsed after receiving perioperative chemotherapy, or progressed on first-line chemotherapy for metastatic disease, were elig...... hiện toàn bộ
Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancer
Investigational New Drugs - - 2010
In Hae Park, Jungsil Ro, Keun Seok Lee, Shi Nae Kim, Young Ho Yun, Byung Ho Nam
Cytotoxicity of diethyldithiocarbamate in human versus rodent cell lines
Investigational New Drugs - Tập 8 Số 2 - Trang 137-142 - 1990
Justin D. Cohen, H. Ian Robins
A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients
Investigational New Drugs - Tập 25 - Trang 139-146 - 2006
Thomas W. Flaig, Daniel L. Gustafson, Lih-Jen Su, Joseph A. Zirrolli, Frances Crighton, Gail S. Harrison, A. Scott Pierson, Rajesh Agarwal, L. Michael Glodé
Silibinin is a polyphenolic flavonoid isolated from milk thistle with anti-neoplastic activity in several in vitro and in vivo models of cancer, including prostate cancer. Silybin-phytosome is a commercially available formulation containing silibinin. This trial was designed to assess the toxicity of high-dose silybin-phytosome and recommend a phase II dose. Silybin-phytosome was administered oral...... hiện toàn bộ
A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma
Investigational New Drugs - Tập 13 Số 2 - Trang 171-174 - 1995
William J. Gradishar, Nicholas J. Vogelzang, Lary J. Kilton, Steven J. Leibach, Alfred Rademaker, Suzanne French, Al B. Benson
Phase II Trial of ixabepilone in patients with cisplatin-refractory germ cell tumors
Investigational New Drugs - Tập 25 - Trang 487-490 - 2007
Darren R. Feldman, G. Varuni Kondagunta, Michelle S. Ginsberg, Nicole Ishill, Sujata Patil, John Cestaro, Eugenie Obbens, Joel Sheinfeld, George J. Bosl, Robert J. Motzer
In a phase I study, ixabepilone, a novel non-taxane microtubule-stabilizing agent, demonstrated activity against both paclitaxel-sensitive and paclitaxel-refractory solid tumors. We conducted a phase II trial of this agent in patients with advanced germ cell tumors (GCT) who were resistant to conventional therapies. Patients with cisplatin-refractory GCT were enrolled in this single-institution, p...... hiện toàn bộ
Phase I study of liposomal daunorubicin in patients with acute leukemia
Investigational New Drugs - Tập 17 - Trang 81-87 - 1999
Jorge Cortes, Susan O'Brien, Elihu Estey, Francis Giles, Michael Keating, Hagop Kantarjian
The dose of anthracyclines used during induction has been identified as a significant prognostic factor in acute leukemias. Liposomal encapsulation of anthracyclines has been proposed as a way of decreasing toxicity and probably increasing efficacy of these agents, therefore allowing the exploration of high-dose anthracycline therapy in acute leukemias. We conducted a phase I study of liposomal da...... hiện toàn bộ
Tổng số: 2,526   
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 10